Bluebird Bio said that its experimental gene therapy helped a French teenager with sickle-cell disease go three months without a blood transfusion. Doctors said the result was encouraging, but that a one-patient study of short duration made it impossible to draw firm conclusions.
from WSJ.com: US Business http://ift.tt/1HDbOiE
via IFTTT
No comments:
Post a Comment